Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
Q1 2026 earnings • in 4 days
See details
BIIB:NASDAQ
Biogen Inc
$184.38
-1.86%
(-3.50) 1D
$184.38
0.00% (0.00)
After hours
Closed: Apr 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB...
Open
$186.65
High
$186.65
Low
$183.17
Mkt. cap
27.06B
Avg. vol.
1.21M
Volume
723.37K
P/E ratio
20.98
52-wk high
$202.41
52-wk low
$115.28
EPS
$8.79
Beta
0.16
Shares outstanding
146.76M
No. of employees
8K
News stories
From sources across the web
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com
Next call in 4 days
Wed, Apr 29, 8:00 AM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (3.02 est.)USD
Revenue / Estimate
-/ (2.25B est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
2.43B
2.65B
2.53B
2.28B
Cost of goods sold
577.90M
946.20M
508.60M
443.40M
Cost of revenue
577.90M
946.20M
508.60M
443.40M
Research and development expenses
426.70M
-
431.80M
501.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
574.60M
581.30M
592.80M
685.20M
Operating expense
1.17B
783.70M
1.25B
1.39B
Total operating expenses
1.75B
1.73B
1.76B
1.83B
Operating income
681.90M
915.60M
778.60M
447.70M
Other non operating income
-500.00K
-3.30M
15.80M
17.40M
EBT including unusual items
311.20M
744.00M
557.30M
-56.00M
EBT excluding unusual items
649.10M
861.60M
748.30M
423.10M
Income tax expense
70.70M
109.20M
90.80M
-7.10M
Effective tax rate
22.72%
14.68%
16.29%
12.68%
Other operating expenses
58.10M
75.00M
87.20M
69.90M
Net income
240.50M
634.80M
466.50M
-48.90M
Net profit margin
9.89%
24.00%
18.40%
-2.15%
Earnings per share
3.02
5.47
4.81
1.99
Interest and investment income
23.90M
32.30M
31.60M
37.20M
Interest expense
-60.00M
-72.60M
-67.40M
-67.50M
Net interest expenses
-36.10M
-40.30M
-35.80M
-30.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
865.10M
1.11B
980.80M
647.90M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer